A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Theravance Biopharma, Inc.
TBPH
$867M
Mkt Cap
$16.86
+0.00%
Theravance Biopharma, Inc. (TBPH) has a 5-year average return on invested capital (ROIC) of -33.5%. This is below average and may indicate limited pricing power.
Theravance Biopharma, Inc. (TBPH) has a market capitalization of $869M. It is classified as a small-cap stock.
Theravance Biopharma, Inc. (TBPH) does not currently pay a regular dividend.
Theravance Biopharma, Inc. (TBPH) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Theravance Biopharma, Inc. (TBPH) reported annual revenue of $107 million in its most recent fiscal year, based on SEC EDGAR filings.
Theravance Biopharma, Inc. (TBPH) has a net profit margin of 98.5%. This is a strong margin indicating high profitability.
Theravance Biopharma, Inc. (TBPH) generated $238 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Theravance Biopharma, Inc. (“we,” “our,” “Theravance Biopharma” or the “Company”) is a biopharmaceutical company primarily focused on the development and commercialization of medicines. Our focus is to deliver medicines that make a difference® in people’s lives. In pursuit of our purpose, we leverage decades of expertise, which has led to the development of the United States (“US”) Food and Drug Administration (the “FDA”) approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (“COPD”). Ampreloxetine, our late-stage investigational once-daily norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension (“nOH”) in patients with Multiple System Atrophy (“MSA”), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 110M | 107M | 64M | 57M | - | - |
| Net Income | 115M | 106M | -56M | -55M | 872M | -199M |
| EPS | $2.26 | $2.06 | $-1.15 | $-1.00 | $11.85 | $-2.87 |
| Free Cash Flow | 0 | 238M | -12M | -29M | 186M | -211M |
| ROIC | 39.4% | - | -29.0% | -16.9% | -20.8% | -67.2% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.64 | 1.02 | 0.00 | 0.37 | -1.82 |
| Dividends/Share | $0.00 | $0.00 | - | - | - | - |
| Operating Income | 1.3M | - | -47M | -56M | -92M | -258M |
| Operating Margin | 1.2% | - | -72.9% | -97.6% | - | - |
| ROE | 39.4% | 44.8% | -29.0% | -16.9% | 197.4% | 62.1% |
| Shares Outstanding | 52M | 51M | 49M | 55M | 74M | 69M |
| Metric | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 57M | 64M | 107M | 110M |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | 169M | 129M | 142M | 174M | 201M | 219M | 261M | 194M | 63M | 41M | 38M | 37M | 32M |
| SG&A | 72M | 90M | 85M | 96M | 97M | 106M | 109M | 99M | 67M | 70M | 69M | 74M | 73M |
| EBIT | -233M | -182M | -180M | -260M | -239M | -252M | -298M | -258M | -92M | -56M | -47M | N/A | 1.3M |
| Op. Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -97.6% | -72.9% | N/A | 1.2% |
| Net Income | -237M | -182M | -191M | -285M | -216M | -236M | -278M | -199M | 872M | -55M | -56M | 106M | 115M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -96.1% | -87.6% | 98.5% | 104.3% |
| Non-Recurring | 2.9M | 2.1M | 303K | 740K | 6.1M | 3.5M | 0 | 20M | 16M | 3.9M | 4.5M | -35K | -35K |
| Returns on Capital | |||||||||||||
| ROIC | -173.8% | -68.4% | -46.7% | -62.6% | -58.1% | -74.6% | -101.7% | -67.2% | -20.8% | -16.9% | -29.0% | N/A | 39.4% |
| ROE | -173.8% | -68.4% | -64.3% | -122.6% | N/A | 171.7% | 105.4% | 62.1% | 197.4% | -16.9% | -29.0% | 44.8% | 39.4% |
| ROA | -130.6% | -57.1% | -40.6% | -52.8% | -43.0% | -48.8% | -63.3% | -47.3% | 177.6% | -11.2% | -15.3% | 25.2% | 24.3% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | -175M | -169M | -99M | -201M | -113M | -238M | -250M | -208M | 187M | -27M | -12M | 239M | 269M |
| Free Cash Flow | -178M | -172M | -101M | -203M | -120M | -241M | -257M | -211M | 186M | -29M | -12M | 238M | 0 |
| Owner Earnings | -222M | -226M | -143M | -254M | -167M | -302M | -317M | -273M | 145M | -54M | -35M | 219M | 227M |
| CapEx | 3.1M | 2.6M | 2.1M | 2.4M | 7.2M | 3.2M | 6.6M | 3.4M | 572K | 2.5M | 332K | 42K | 0 |
| Maint. CapEx | 3.3M | 3.0M | 3.1M | 4.0M | 3.2M | 3.3M | 3.3M | 3.5M | 2.6M | 1.9M | 1.6M | 1.5M | 24M |
| Growth CapEx | 0 | 0 | 0 | 0 | 4.1M | 0 | 3.3M | 0 | 0 | 588K | 0 | 0 | 0 |
| D&A | 3.3M | 3.0M | 3.1M | 4.0M | 3.2M | 3.3M | 3.3M | 3.5M | 2.6M | 1.9M | 1.6M | 1.5M | 24M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 129M | 197M | 445K | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 15.7% | 31.6% | 0.1% | 0.0% | 0.0% |
| Stock-Based Comp | 43M | 54M | 41M | 49M | 51M | 60M | 63M | 62M | 40M | 25M | 21M | 18M | 18M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 5.3M | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||||||||
| Net Debt | -88M | -113M | -122M | -235M | -425M | 123M | 326M | 393M | N/A | -111M | N/A | N/A | -420M |
| Cash & Equiv. | 89M | 113M | 345M | 89M | 378M | 58M | 81M | 90M | 298M | 40M | 38M | 168M | 420M |
| Long-Term Debt | 0 | 0 | 222M | 224M | 454M | 455M | 619M | 616M | N/A | 0 | N/A | N/A | N/A |
| Debt/Equity | 0.00 | 0.00 | 0.64 | 1.94 | -8.81 | -2.03 | -2.04 | -1.82 | 0.37 | 0.00 | 1.02 | 0.64 | 0.00 |
| Interest Coverage | N/A | N/A | -128.5 | -30.4 | -22.8 | -7.9 | -34.8 | -30.2 | -14.4 | -23.8 | -8.4 | N/A | N/A |
| Equity | 290M | 243M | 350M | 115M | -52M | -224M | -304M | -339M | 442M | 213M | 176M | 297M | 291M |
| Total Assets | 338M | 300M | 639M | 441M | 560M | 409M | 469M | 375M | 607M | 382M | 354M | 486M | 472M |
| Total Liabilities | 48M | 57M | 289M | 326M | 612M | 633M | 773M | 713M | 166M | 169M | 179M | 189M | -4.9M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0 | 0 |
| Retained Earnings | -139M | -322M | -512M | -798M | -1.0B | -1.2B | -1.5B | -1.7B | -854M | -909M | -966M | -860M | -865M |
| Working Capital | 234M | 188M | 479M | 316M | 434M | 227M | 270M | 191M | 325M | 109M | 129M | 380M | 386M |
| Current Assets | 275M | 237M | 529M | 379M | 533M | 338M | 393M | 250M | 353M | 134M | 161M | 418M | 418M |
| Current Liabilities | 41M | 49M | 49M | 63M | 99M | 112M | 124M | 59M | 29M | 25M | 32M | 38M | 32M |
| Per Share Data | |||||||||||||
| EPS | -7.46 | -5.34 | -4.26 | -5.45 | -3.99 | -4.25 | -4.46 | -2.87 | 11.85 | -1.00 | -1.15 | 2.06 | 2.26 |
| Owner EPS | -6.98 | -6.62 | -3.20 | -4.85 | -3.10 | -5.43 | -5.08 | -3.93 | 1.97 | -0.98 | -0.70 | 4.25 | 4.40 |
| Book Value | 9.12 | 7.12 | 7.82 | 2.20 | -0.96 | -4.02 | -4.87 | -4.87 | 6.00 | 3.86 | 3.58 | 5.77 | 5.64 |
| Cash Flow/Share | -5.51 | -4.95 | -2.21 | -3.84 | -2.09 | -4.28 | -4.02 | -2.99 | 2.54 | -0.49 | -0.24 | 4.64 | 2.69 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 | 0.00 |
| Shares Out. | 31.8M | 34.1M | 44.8M | 52.4M | 54.0M | 55.6M | 62.3M | 69.5M | 73.6M | 55.2M | 49.1M | 51.4M | 51.5M |
| Valuation | |||||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.9 | N/A | N/A | N/A | 7.5 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 4.4 | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 332.8 |
| Price/Book | 1.6 | 2.3 | 4.0 | 12.9 | N/A | N/A | N/A | N/A | 1.9 | 2.9 | 2.7 | N/A | 3.0 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 9.9 | 6.9 | N/A | 7.9 |
| FCF Yield | -37.5% | -30.7% | -7.1% | -13.7% | -9.5% | -16.8% | -22.6% | -28.5% | 22.7% | -4.7% | -2.5% | N/A | N/A |
| Market Cap | 475M | 558M | 1.4B | 1.5B | 1.3B | 1.4B | 1.1B | 742M | 822M | 624M | 470M | 0 | 869M |
| Avg. Price | 24.14 | 15.56 | 24.12 | 33.18 | 26.36 | 21.26 | 21.89 | 14.45 | 9.73 | 10.34 | 9.02 | 0.00 | 16.86 |
| Year-End Price | 14.96 | 16.35 | 31.61 | 28.43 | 23.43 | 25.78 | 18.21 | 10.68 | 11.17 | 11.31 | 9.59 | 0.00 | 16.86 |
Theravance Biopharma, Inc. passes 1 of 9 quality checks, indicating weak fundamentals.
At current prices, the estimated annualized return to fair value is +1.8%.
Theravance Biopharma, Inc. (TBPH) has a debt-to-equity ratio of 0.64. This indicates moderate leverage.
Theravance Biopharma, Inc. (TBPH) reported earnings per share (EPS) of $2.06 in its most recent fiscal year.
Theravance Biopharma, Inc. (TBPH) has a return on equity (ROE) of 44.8%. This indicates the company generates strong returns for shareholders.
The Ledger Terminal provides 14 years of financial data for Theravance Biopharma, Inc. (TBPH), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Theravance Biopharma, Inc. (TBPH) has a book value per share of $5.77, based on its most recent annual SEC filing.